Results 31 to 40 of about 7,556 (242)

Modified Therapeutic Antibodies: Improving Efficacy

Engineering, 2021
The prosperity of the biotherapeutics market reflects the feasibility and effectiveness of therapeutic antibodies for the treatment of cancers, inflammatory disorders, and refractory infections.
Ji-Min Dai, Xue-Qin Zhang, Jing-Yao Dai, Xiang-Min Yang, Zhi-Nan Chen   +4 more
doaj  

Advances in therapeutic Fc engineering - modulation of IgG associated effector functions and serum half-life

Frontiers in Immunology, 2016
Today monoclonal immunoglobulin gamma (IgG) antibodies have become a major option in cancer therapy especially for the patients with advanced or metastatic cancers.
Abhishek Saxena, Donghui Wu
doaj   +1 more source

B Cell-Based Seamless Engineering of Antibody Fc Domains. [PDF]

PLoS ONE, 2016
Engineering of monoclonal antibodies (mAbs) enables us to obtain mAbs with additional functions. In particular, modifications in antibody's Fc (fragment, crystallizable) region can provide multiple benefits such as added toxicity by drug conjugation ...
Koji Hashimoto, Kohei Kurosawa, Akiho Murayama, Hidetaka Seo, Kunihiro Ohta   +4 more
doaj   +1 more source

Antibody degradation in tobacco plants: a predominantly apoplastic process. [PDF]

, 2011
BACKGROUND: Interest in using plants for production of recombinant proteins such as monoclonal antibodies is growing, but proteolytic degradation, leading to a loss of functionality and complications in downstream purification, is still a serious problem.
Drake, PM, Hehle, VK, Ma, JK, Paul, MJ, van Dolleweerd, CJ   +4 more
core   +2 more sources

High-level fed-batch fermentative expression of an engineered Staphylococcal protein A based ligand in E. coli: purification and characterization [PDF]

, 2015
The major platform for high level recombinant protein production is based on genetically modified microorganisms like Escherichia coli (E. coli) due to its short dividing time, ability to use inexpensive substrates and additionally, its genetics is ...
Fernández Lahore, Marcelo, Gorrepati, Kanaka Durga Devi, Grasselli, Mariano, Kangwa, Martin, Polat, Ayse Nur, Yelemane, Vikas   +5 more
core   +1 more source

Camelid VHHs Fused to Human Fc Fragments Provide Long Term Protection Against Botulinum Neurotoxin A in Mice

Toxins, 2019
The bacterium Clostridium botulinum is the causative agent of botulism—a severe intoxication caused by botulinum neurotoxin (BoNT) and characterized by damage to the nervous system. In an effort to develop novel C.
Svetlana A. Godakova, Anatoly N. Noskov, Irina D. Vinogradova, Galina A. Ugriumova, Andrey I. Solovyev, Ilias B. Esmagambetov, Amir I. Tukhvatulin, Denis Y. Logunov, Boris S. Naroditsky, Dmitry V. Shcheblyakov, Aleksandr L. Gintsburg   +10 more
doaj   +1 more source

Comparison of LC and LC/MS Methods for Quantifying N-Glycosylation in Recombinant IgGs [PDF]

, 2008
High-performance liquid chromatography (LC) and liquid chromatography/electrospray ionization time-of-flight mass spectrometry (LC/ESI-MS) methods with various sample preparation schemes were compared for their ability to identify and quantify glycoforms
Bondarenko, Pavel V., Gadgil, Himanshu S., Pipes, Gary, Sinha, Sandipan, Topp, Elizabeth M., Treuheit, Michael J.   +5 more
core   +1 more source

Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2

Frontiers in Immunology, 2022
Monoclonal antibodies (mAbs) targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein have demonstrated clinical efficacy in preventing or treating coronavirus disease 2019 (COVID-19), resulting in the emergency use ...
Yun Ji, Qi Zhang, Lin Cheng, Jiwan Ge, Ruoke Wang, Mengqi Fang, Eric M. Mucker, Peng Chen, Ji Ma, Rui Zhang, Chunming Li, Holly Hammond, Lauren Baracco, Michael Holbrook, Matthew Frieman, Zheng Zhang, Xinquan Wang, Jay W. Hooper, Linqi Zhang, Qing Zhu   +19 more
doaj   +1 more source

Differential Inhibition of Human Atherosclerotic Plaque-Induced Platelet Activation by Dimeric GPVI-Fc and Anti-GPVI Antibodies: Functional and Imaging Studies. [PDF]

, 2015
BACKGROUND: Glycoprotein VI (GPVI) is the essential platelet collagen receptor in atherothrombosis, but its inhibition causes only a mild bleeding tendency. Thus, targeting this receptor has selective antithrombotic potential.
Bianchini, Mariaelvy, Brandl, Richard, Elia, Natalie, Farndale, Richard, Faussner, Alexander, Goyal, Pankaj, Jamasbi, Janina, Jung, Stephanie, Lorenz, Reinhard, Megens, Remco TA, Münch, Götz, Sherman, Shachar, Siess, Wolfgang, Ungerer, Martin, Walker, Adam, Weber, Christian   +15 more
core   +2 more sources

Fc gamma receptor IIIb binding of individual antibody proteoforms resolved by affinity chromatography–mass spectrometry

mAbs, 2021
The crystallizable fragment (Fc) of immunoglobulin G (IgG) activates key immunological responses by interacting with Fc gamma receptors (FcɣR). FcɣRIIIb contributes to neutrophil activation and is involved in antibody-dependent cellular cytotoxicity ...
Steffen Lippold, Alexander Knaupp, Arnoud H. de Ru, Rayman T. N. Tjokrodirijo, Peter A. van Veelen, Erwin van Puijenbroek, Steven W. de Taeye, Dietmar Reusch, Gestur Vidarsson, Manfred Wuhrer, Tilman Schlothauer, David Falck   +11 more
doaj   +1 more source